References
- The Lists. 25 clinical failures of Q1 2017. Genetic Engineering & Biotechnology News. https://www.genengnews.com/the-lists/25-clinical-failures-of-q1-2017/77900897.
- Sánchez-Serrano I, Pfeifer T, Chaguturu R. Disruptive approaches to accelerate drug discovery and development. Part I. Tools, technologies and the core model. Drug Discovery World. 2018;( Spring):39–52.
- Fliri A, Manavaskam P, Kajiji S, et al. Disruptive approaches to accelerate drug discovery. Part II: emergent intelligence, a new paradigm for drug discovery. Drug Discovery World. 2018;( Summer). in press.
- Palmer M, Chaguturu R. Academia–pharma partnerships for novel drug discovery: essential or nice to have? Expert Opin Drug Discov. 2017 Jun;12(6):537–540.
- Roy A, Patwardhan B, Chaguturu R. Reigniting pharmaceutical innovation through holistic drug targeting. Drug Discovery World. 2016;( Summer):45–55.
- Titze-de-Almeida R, David C, Titze-de-Almeida S. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017 Jul;34(7):1339–1363.
- Butler GS, Overall CM. Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov. 2009 Dec;8(12):935–948.
- Gu S, Cui D, Chen X, et al. PROTACs: an emerging targeting technique for protein degradation in drug discovery. Bioessays. 2018 Apr;40(4):e1700247.
- Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv. 2018 Jan–Feb;36(1):328–334.
- Fellmann C, Gowen BG, Lin PC, et al. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017 Feb;16(2):89–100.
- Vincent F, Loria P, Pregel M, et al. Developing predictive assays: the phenotypic screening “rule of 3”. Sci Transl Med. 2015 Jun 24;7(293):293ps15.
- Tang S, Xie M, Cao N, et al. Patient-specific induced pluripotent stem cells for disease modeling and phenotypic drug discovery. J Med Chem. 2016 Jan 14;59(1):2–15.
- Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018 Apr;15(141):20170387. pii.
- Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437–1452.e17.
- Keenan, et al. The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations. Cell Syst. 2018;6(1):13–24.
- Stathias V, et al. Sustainable data and metadata management at the BD2K-LINCSData Coordination and Integration Center.
- Smith S. 97 Startups Using Artificial Intelligence in Drug Discovery. [cited 2018 Aug 18]. Available from: https://blog.benchsci.com/startups-using-artificial-intelligence-in-drug-discovery.
- Vaidya ADB, Dhami H, Shukla N. Nutraceuticals, naturals and nutritionals-a discovery path from ayurveda. NuFFooDS Spectr. 2013;1(1):16–17.
- Pithva A, Pithva A. Current prospects of herbal medicines in the world. Res Rev J Pharmacogn Phytochem. 2016;4:60–67.
- Yuan H, Ma Q, Ye L, et al. The traditional medicine and modern medicine from natural products. Molecules. 2016;21:559–577.
- Shen B. A new golden age of natural products drug discovery. Cell. 2015;163:1297–1300.
- Vaidya AB. Reverse pharmacological correlates of ayurvedic drug actions. Ind J Pharmacol. 2006;38:311–315.
- Patwardhan B, Vaidya AB. Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches. Indian J Exp Biol. 2010;48:220–227.
- Jain S, Murthy P. The other Bose: an account of missed opportunities in the history of neurobiology in India. Curr Sci. 2009;97:266–269.
- Roy P. Global pharma and local science: the untold story of reserpine. Indian J Psychiatry. 2018;60:277–283.